Results 21 to 30 of about 16,896 (199)
Asian Journal of Andrology, 2016 In a large clinical trial, finasteride reduced the rate of low-grade prostate cancer (PCa) while increasing the incidence of high-grade cancer. Whether finasteride promotes the development of high-grade tumors remains controversial.
Yi-Nong Niu +6 more
doaj +1 more source
American Journal of Men's Health, 2019 Finasteride is commonly used for treatment of alopecia. Because finasteride is a cause of gynecomastia, there is concern regarding the continuation of finasteride therapy after mastectomy.
Seung Geun Lee MD, PhD +9 more
doaj +1 more source
Preparation of finasteride capsules-loaded drug nanoparticles: formulation, optimization, in vitro, and pharmacokinetic evaluation [PDF]
, 2016 Tarek A Ahmed1,2 1Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Kingdom of Saudi Arabia; 2Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Al-Azhar University, Cairo,
Tarek Ahmed, Ahmed TA
core +1 more source
Metabolites, 2020 Male pattern baldness (MPB) has been associated with dihydrotestosterone (DHT) expression. Finasteride treats MPB by inhibiting 5-alpha reductase and blocking DHT production.
Yu Ra Lee +9 more
doaj +1 more source
Does treatment with dutasteride or finasteride has impact on renal morphology? Experimental study
Acta Cirúrgica Brasileira, 2021 Purpose: To investigate whether renal modifications occur following treatment with dutasteride or finasteride. Methods: Twenty-four male rats were divided into three groups: control (that received distilled water), dutasteride (0.5 mg/kg/day), and ...
Marcello Henrique Araújo da Silva +4 more
doaj +1 more source
The effectiveness of reducing the daily dose of finasteride in men with benign prostatic hyperplasia
BMC Urology, 2002 Background Finasteride, a 5 alpha reductase inhibitor, is an established treatment for benign prostatic hyperplasia. The recommended dosage is 5 mg a day, however case reports have show effectiveness with lower doses.
Geller Jack, Sullivan Michael J
doaj +1 more source
Pregnancy and neonatal outcome with maternal exposure to finasteride: Case series
Journal of Dermatology and Dermatologic Surgery, 2021 Background: Finasteride, a type II 5-α reductase inhibitor, is approved for the management of benign prostate hyperplasia and male pattern hair loss. Finasteride is used off-label for female pattern hair loss. In utero fetal exposure to finasteride might
Hessah F BinJadeed, Abdulmajeed Alajlan
doaj +1 more source
Anti-proliferative activities of finasteride in benign prostate epithelial cells require stromal fibroblasts and c-Jun gene. [PDF]
PLoS ONE, 2017 This study aimed to identify the role of mouse fibroblast-mediated c-Jun and IGF-1 signaling in the therapeutic effect of finasteride on benign prostatic epithelial cells.
Kai Wang +5 more
doaj +1 more source
Finasteride interferes with prostaglandin-induced CatSper signalling in human sperm
, 2021 Ca2+ signalling controls human sperm functions necessary for successful fertilization. Multiple endocrine-disrupting chemicals have been found to activate the CatSper Ca2+ channel and thereby interfering with Ca2+ signalling in human sperm.
Rehfeld, Anders +3 more
core +1 more source
The World Journal of Men's Health, 2019 Finasteride is primarily used to treat benign prostatic hyperplasia (BPH) and male androgenetic alopecia (MAA). Five-alpha reductase inhibitors (5α-RIs) could induce male sexual dysfunction due to their effects on testosterone and dihydrotestos-terone ...
Yu Seob Shin +3 more
doaj +1 more source